D-dimer and platelet aggregability are related to thrombotic events in patients with peripheral arterial occlusive disease

European Heart Journal

Volumn 23, Issue 16, 2002, Pages 1309-1316

  Komarov, Andrey L ^a   Panchenko, E P ^a   Dobrovolsky, A B ^a   Karpov, Yu A ^a   Deev, A D ^b   Titaeva, E V ^a   Davletov, K K ^a   Eshkeeva, A R ^a   Markova, L A ^a  

^a INSTITUTE OF EXPERIMENTAL CARDIOLOGY   (Russian Federation)

^b NATIONAL MEDICAL RESEARCH CENTER FOR THERAPY AND PREVENTIVE MEDICINE   (Russian Federation)

Author keywords

Atherosclerosis; D dimer; Platelet aggregation; Thrombotic event

Indexed keywords

ADENOSINE DIPHOSPHATE; ANTIPLASMIN; BETA THROMBOGLOBULIN; D DIMER; FIBRINOGEN; PLASMIN; TISSUE PLASMINOGEN ACTIVATOR; BIOLOGICAL MARKER; FIBRIN DEGRADATION PRODUCT; FIBRIN FRAGMENT D;

ADULT; AGED; ARTICLE; CEREBROVASCULAR DISEASE; DIABETES MELLITUS; FEMALE; HEMOSTASIS; HUMAN; INTERMITTENT CLAUDICATION; MAJOR CLINICAL STUDY; MALE; MULTIPLE REGRESSION; PERIPHERAL OCCLUSIVE ARTERY DISEASE; PRIORITY JOURNAL; THROMBOCYTE AGGREGATION; THROMBOSIS; ARTERIOSCLEROSIS; BLOOD; FOLLOW UP; MIDDLE AGED; PERIPHERAL VASCULAR DISEASE; PROGNOSIS; RISK ASSESSMENT; RISK FACTOR; STATISTICAL MODEL;

ADULT; AGED; ARTERIOSCLEROSIS; BIOLOGICAL MARKERS; FEMALE; FIBRIN FIBRINOGEN DEGRADATION PRODUCTS; FOLLOW-UP STUDIES; HUMANS; INTERMITTENT CLAUDICATION; LOGISTIC MODELS; MALE; MIDDLE AGED; PERIPHERAL VASCULAR DISEASES; PLATELET AGGREGATION; PROGNOSIS; RISK ASSESSMENT; RISK FACTORS; THROMBOSIS;

EID: 0036669005     PISSN: 0195668X     EISSN: None     Source Type: Journal    
DOI: 10.1053/euhj.2001.3116     Document Type: Article

References (39)

1. Falk E, Fernandez-Oritz A. Role of thrombosis in atherosclerosis and its complications. Am J Cardiol 1995; 75: 5B-11B.
2. Fuster V, Badimon L, Badimon JJ, Chesebro JH. The pathogenesis of coronary artery disease and the acute coronary syndromes (2). N Engl J Med 1992; 326: 310-8.
3. Fuster V, Fallon JT, Badimon JJ, Nemerson Y. The unstable atherosclerotic plaque: Clinical significance and therapeutic intervention. Thromb Haemost 1997; 78: 247-55.
4. Meade TW, Mellows S, Brozovic M et al. Haemostatic function and ischaemic heart disease: Principal results of the Northwick Park Heart Study. Lancet 1986; 2: 533-7.
5. Wilhelmsen L, Svardsudd K, Korsan-Bengtsen K, Larsson B, Welin L, Tibblin G. Fibrinogen as a risk for stroke and myocardial infarction. N Engl J Med 1984; 311: 501-5.
6. Kannel WB, Wolf PA, Castelli WP, D'Agostino RB. Fibrinogen and risk of cardiovascular disease. The Framingham Study. JAMA 1987; 258: 1183-6.
7. Ridker PM, Hennekens CH, Cerskus A, Stampfer MJ. Plasma concentration of cross-linked fibrin degradation product (D-dimer) and the risk of future myocardial infarction among apparently healthy men. Circulation 1994; 90: 2236-40.
8. Fowkes FGR, Love GDO, Housley E et al. Cross-linked fibrin degradation products, progression of peripheral arterial disease, and risk of coronary heart disease. Lancet 1993; 342: 84-6.
9. Smith FB, Lee AJ, Fowkes FGR et al. Hemostatic factors as predictors of ischemic heart disease and stroke in the Edinburgh artery study. Arterioscler Thromb Vasc Biol 1997; 17: 3321-5.
10. Jansson JH, Nilsson TK, Olofsson BO. Tissue plasminogen activator and other risk factors as predictors of cardiovascular events in patients with severe angina pectoris. Eur Heart J 1991; 12: 157-61.
11. Jansson JH, Olofsson BO, Nilsson TK. Predicative value of tissue plasminogen activator mass concentration on long-term mortality in patients with coronary artery disease. Circulation 1993; 88: 2030-4.
12. Ridker PM, Vaughan DE, Stampfer MJ, Manson JE, Hennekens CH. Endogenous tissue-type plasminogen activator and risk of myocardial infarction. Lancet 1993; 341: 1165-8.
13. Ridker PM, Hennekens CH, Stampfer MJ, Manson JE, Vaughan DE. Prospective study of endogenous tissue-type plasminogen activator and stroke. Lancet 1994; 343: 930-43.
14. Herren T, Stricker H, Haeberli A, Do DD, Straub PW. Fibrin formation and degradation in patients with atherosclerotic disease. Circulation 1994; 90: 2679-86.
15. Lassila R, Peltonen S, Lepantalo M, Saarinen O, Kauhanen P, Manninen V. Severity of peripheral atherosclerosis is associated with fibrinogen and degradation of cross-linked fibrin. Arterioscler Thromb 1993; 13: 1738-42.
16. Dormandy J, Mahir M, Ascady G et al. Fate of the patient with chronic leg ischemia. J Cardiovasc Surg 1989; 30: 50-7.
17. Smith GD, Shipley MJ, Rose G. Intermittent claudication, heart disease risk factors, and mortality: The Whitehall Study. Circulation 1990; 82: 1925-31.
18. Becker U, Bortl K, Wahlefeld AN. A functional photometric assay for plasma fibrinogen. Thromb Res 1984; 35: 475-84.
19. Chandler WL, Loo SC, Nguyen SV et al. Standardisation of methods for measuring plasminogen activator inhibitor activity in human plasma. Clin Chem 1989; 35: 787-93.
20. Perkins JM, Collin J, Creasy TS, Fletcher EW, Morris PJ. Exercise training versus angioplasty for stable claudication. Long and medium term results of a prospective, randomised trial. Eur J Vasc Endovasc Surg 1996; 11: 409-13.
21. Jelnes R, Gaardsting O, Hougaard Jensen K, Baekgaard N, Tonnesen KH, Schroeder T. Fate in intermittent claudication: Outcome and risk factors. Br Med J 1986; 293: 1137-40.
22. Hertzer NR, Beven EG, Young JR et al. Coronary artery disease in peripheral vascular patients - A classification of 1000 coronary angiograms and results of surgical management. Ann Surg 1984; 199: 223-33.
23. Spürc P, Angelkort B, Selter P. Incidence of atherosclerotic lesions of the carotid arteries in chronic peripheral arterial disease and myocardial infarction. Angiology 1989; 40: 39-43.
24. Criqui MH, Langer RD, Fronek A et al. Mortality over a period of 10 years in patients with peripheral arterial occlusive disease. N Engl J Med 1992; 326: 381-6.
25. Panchenko E, Dobrovolsky A, Davletov K. D-dimer and fibrinolysis in patients with various degrees of atherosclerosis. Eur Heart J 1995; 16: 38-42.
26. Lowe GDO, Fowkes FGR, Dawes J, Donnan PT, Lennie SE, Housley E. Blood viscosity, fibrinogen, and activation of coagulation and leukocytes in peripheral arterial disease and the normal population in the Edinburgh Arterial Study. Circulation 1993; 87: 1915-20.
27. Prentice CRM. Platelets and atherosclerosis. Eur Heart J Supplements 1999; 1 (Suppl A): A3-A7.
28. Cortellaro M, Cofrancesco E, Boschetti C et al. Increased fibrin turnover and high PAI-1 activity as predictors of ischemic events in arteriosclerotic patients. A case-control study. Arterioscler Thromb 1993; 13: 1412-7.
29. Lowe GDO, Rumley A. Use of fibrinogen and fibrin D-dimer in prediction of arterial thrombotic events. Thromb Haemost 1999; 82: 667-72.
30. Peener EP, King GL. Vascular dysfunction in diabetes mellitus. Lancet 1997; 350 (Suppl 1): S9-S13.
31. Antiplatelet Trialists' Collaboration. Collaborative overview of randomised trials of antiplatelet therapy - I: Prevention of death, myocardial infarction and stroke by prolonged antiplatelet therapy in various categories of patients. Br Med J 1994; 308: 81-106.
32. CAPRIE Steering Committee. A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). Lancet 1996; 348: 1329-39.
33. Schomig A, Neumann FJ, Kastrati A et al. A randomised comparison of antiplatelet and anticoagulant therapy after the placement of coronary-artery stents. N Engl J Med 1996; 334: 1084-9.
34. Schomig A, Neumann FJ, Walter H et al. Coronary stent placement in patients with acute myocardial infarction: Comparison of clinical and angiographic outcome after randomisation to antiplatelet or anticoagulant therapy. J Am Coll Cardiol 1997; 29: 28-34.
35. Bhatt DL, Topol EJ. Current role of platelet glycoprotein IIb/IIIa inhibitors in acute coronary syndromes. JAMA 2000; 284: 1549-58.
36. Mannarino E, Pasqualini L, Innocente S et al. Efficacy of low-molecular-weight heparin in the management of intermittent claudication. Angiology 1991; 42: 1-7.
37. Calbaro A, Piarulli F, Milan D, Rossi A, Coscetti G, Crepaldi G. Clinical assessment of low molecular weight heparin effects in peripheral vascular disease. Angiology 1993; 44: 188-95.
38. Thrombosis prevention trial: randomised trial of low-intensity oral anticoagulation with warfarin and low-dose aspirin in the primary prevention of ischemic heart disease in men at increased risk. The Medical Research Council's General Practice Research Framework. Lancet 1998; 351: 233-41.
39. Loewen P, Sunderji R, Gin K. The efficacy and safety of combination warfarin and ASA therapy: A systematic review of the literature and update of guidelines. Can J Cardiol 1998; 14: 717-26.